{"id":755,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"bremelanotide-reconnect-phase-3-trials-and-fda-label","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","title":{"rendered":"Essais sur le bremelanotide RECONNECT\u00a0: param\u00e8tres, s\u00e9curit\u00e9 et port\u00e9e du FDA"},"content":{"rendered":"

Le bremelanotide poss\u00e8de un v\u00e9ritable dossier de m\u00e9dicament fini approuv\u00e9 par FDA, mais sa port\u00e9e est \u00e9troite. Les essais RECONNECT ont \u00e9tudi\u00e9 des femmes pr\u00e9m\u00e9nopaus\u00e9es pr\u00e9sentant un HSDD acquis et g\u00e9n\u00e9ralis\u00e9, et non des hommes, une am\u00e9lioration des performances ou un mat\u00e9riel de recherche PT-141 g\u00e9n\u00e9rique.<\/p>

Les preuves en un coup d'\u0153il<\/h2>
  • Les essais 3 en deux phases ont randomis\u00e9 les femmes 1,267\u00a0; Les 1,202 faisaient partie de la population d\u2019efficacit\u00e9.<\/li>
  • Les changements entre les groupes ont favoris\u00e9 le bremelanotide pour les crit\u00e8res de d\u00e9sir et de d\u00e9tresse, mais une mesure post-hoc d'un \u00e9v\u00e9nement satisfaisant ne diff\u00e9rait pas de mani\u00e8re significative.<\/li>
  • Des naus\u00e9es, des bouff\u00e9es vasomotrices et des maux de t\u00eate sont survenus chez au moins 10% et \u00e9taient plus fr\u00e9quents qu'avec le placebo.<\/li><\/ul><\/div><\/div>
    \"Visualisation
    Illustration originale de recherche \u00e9ditoriale. Il ne s\u2019agit pas d\u2019une figure d\u2019\u00e9tude, d\u2019une image d\u2019un patient, d\u2019une photographie de produit, d\u2019un r\u00e9sultat d\u2019analyse fourni ou d\u2019une repr\u00e9sentation d\u2019un lot du catalogue.<\/figcaption><\/figure>

    Dossier d'\u00e9tudes<\/h2>

    Les crit\u00e8res d'\u00e9valuation coprimaires \u00e9taient la modification du score du domaine de d\u00e9sir FSFI et un \u00e9l\u00e9ment de d\u00e9tresse du FSDS-DAO. Les diff\u00e9rences de d\u00e9sir sp\u00e9cifiques \u00e0 l'\u00e9tude \u00e9taient 0.30 et 0.42\u00a0; les diff\u00e9rences de d\u00e9tresse \u00e9taient de \u22120.37 et \u22120.29. La signification statistique ne d\u00e9crit pas \u00e0 elle seule l\u2019ampleur ou la pertinence des avantages pour chaque individu.<\/p>

    Conception<\/strong>Deux essais de phase 3 identiques, randomis\u00e9s, en double aveugle et contr\u00f4l\u00e9s par placebo<\/span><\/div>
    Randomis\u00e9<\/strong>1,267 femmes pr\u00e9m\u00e9nopaus\u00e9es<\/span><\/div>
    Diff\u00e9rence de d\u00e9sir int\u00e9gr\u00e9e<\/strong>0.35 versus placebo\u00a0; P<0.001<\/span><\/div>
    Diff\u00e9rence de d\u00e9tresse int\u00e9gr\u00e9e<\/strong>\u22120.33 versus placebo ; P<0.001<\/span><\/div>
    Limite de l'\u00e9tiquette<\/strong>Non indiqu\u00e9 pour les femmes, les hommes, les enfants m\u00e9nopaus\u00e9s ou pour l'am\u00e9lioration des performances<\/span><\/div><\/div><\/div>

    R\u00e9sultats en contexte<\/h2>

    L'article ne rapporte aucune diff\u00e9rence significative entre les groupes dans le pourcentage d'\u00e9v\u00e9nements sexuels satisfaisants dans une analyse post-hoc. En pr\u00e9servant ce r\u00e9sultat nul, l'enregistrement est plus informatif qu'un r\u00e9sum\u00e9 des avantages uniquement.<\/p>

    L'\u00e9tiquetage actuel de DailyMed identifie Vyleesi comme \u00e9tant une injection de bremelanotide sous NDA 210557 et r\u00e9pertorie l'augmentation transitoire de la pression art\u00e9rielle, la diminution de la fr\u00e9quence cardiaque, les naus\u00e9es et l'hyperpigmentation focale parmi les informations de s\u00e9curit\u00e9 importantes. Ce label appartient \u00e0 la formulation approuv\u00e9e et non \u00e0 un \u00e9l\u00e9ment du catalogue de recherche.<\/p>

    Ce que la preuve ne peut \u00e9tablir<\/h2>

    La population de preuves et l\u2019indication sont sp\u00e9cifiques\u00a0; les affirmations plus larges sur la performance sexuelle ne sont pas \u00e9tay\u00e9es.<\/p>

    Les essais pivots ont \u00e9t\u00e9 financ\u00e9s par l'industrie.<\/p>

    Un fragment actif approuv\u00e9 ne fait pas d\u2019un mat\u00e9riau provenant de sources ind\u00e9pendantes un m\u00e9dicament approuv\u00e9.<\/p>","protected":false},"excerpt":{"rendered":"

    Le bremelanotide poss\u00e8de un v\u00e9ritable dossier de m\u00e9dicament fini approuv\u00e9 par FDA, mais sa port\u00e9e est \u00e9troite. Les essais RECONNECT ont \u00e9tudi\u00e9 des femmes pr\u00e9m\u00e9nopaus\u00e9es pr\u00e9sentant un HSDD acquis et g\u00e9n\u00e9ralis\u00e9, et non des hommes, une am\u00e9lioration des performances ou un mat\u00e9riel de recherche PT-141 g\u00e9n\u00e9rique.<\/p>","protected":false},"author":1,"featured_media":739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Published evidence review","pim_evidence_level":"Two randomized phase 3 trials plus current FDA-approved prescribing information","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nBremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope<\/title>\n<meta name=\"description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\" \/>\n<meta property=\"og:description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essais sur le bremelanotide RECONNECT\u00a0: param\u00e8tres, s\u00e9curit\u00e9 et port\u00e9e du FDA","description":"Le bremelanotide poss\u00e8de un v\u00e9ritable dossier de m\u00e9dicament fini approuv\u00e9 par FDA, mais sa port\u00e9e est \u00e9troite. Les essais RECONNECT ont \u00e9tudi\u00e9 des femmes pr\u00e9m\u00e9nopaus\u00e9es pr\u00e9sentant des troubles acquis, g\u00e9n\u00e9raux\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_locale":"fr_FR","og_type":"article","og_title":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","og_description":"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026","og_url":"https:\/\/nhdbio.com\/fr\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","url":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","name":"Essais sur le bremelanotide RECONNECT\u00a0: param\u00e8tres, s\u00e9curit\u00e9 et port\u00e9e du FDA","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"Le bremelanotide poss\u00e8de un v\u00e9ritable dossier de m\u00e9dicament fini approuv\u00e9 par FDA, mais sa port\u00e9e est \u00e9troite. Les essais RECONNECT ont \u00e9tudi\u00e9 des femmes pr\u00e9m\u00e9nopaus\u00e9es pr\u00e9sentant des troubles acquis, g\u00e9n\u00e9raux\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=755"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}